MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Selegiline drives autophagic secretion of α-synuclein

Y. Nakamura, S. Arawaka (Takatsuki, Japan)

Meeting: 2023 International Congress

Abstract Number: 1486

Keywords: Alpha-synuclein, MAO-B inhibitors, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: Our aim is to elucidate how selegiline drives extracellular secretion of α-synuclein (αS) and whether selegiline-induced αS secretion affects cell-to-cell transmission of αS.

Background: Extracellular αS secretion play a key role in developing cell-to-cell transmission of αS pathology in progressive neurodegeneration of α-synucleinopathies. Previous studies have demonstrated that αS is secreted under physiological conditions in neuronal cell lines and primary neurons. We have previously shown that monoamine oxidase-B inhibition facilitates extracellular αS secretion in SH-SY5Y cells (1). However, its molecular mechanisms and its effect to cell-to-cell transmission of αS remain unclear.

Method: Using mouse primary cortical neurons or SH-SY5Y cells stably expressing αS, we assessed effects of selegiline, monoamine oxidase-B inhibitor, on extracellular secretion of αS via an autophagic mechanism. To investigate the effect of selegiline-induced αS secretion on cell-to-cell transmission of αS, we treated primary neurons with the conditioned medium of PBS or selegiline-treated SH-SY5Y cells.

Results: Selegiline enhanced αS secretion in mouse primary cortical neurons. Secretion of αS induced by selegiline was suppressed by intracellular calcium chelator, BAPTA-AM. siRNA-mediated knockdown of Atg5 inhibited selegiline-induced αS and p62 secretions in SH-SY5Y cells stably expressing αS. Selegiline increased LC3-II to β-actin ratio and decreased intracellular p62 levels in primary neurons. Immunofluorescence analysis revealed that selegiline induced colocalization of αS and LC3-II in primary neurons. Blocking amphisome formation by tetanus toxin significantly reduced selegiline-induced αS and p62 secretions. Selegiline didn’t affect colocalization of αS and LAMP1 in primary neurons. While selegiline increases αS secretion in non-exosome enriched extracellular vesicle (EV) fraction, selegiline didn’t affect αS secretion in EV fraction. When primary neurons were exposed with the conditioned medium of PBS or selegiline-treated SH-SY5Y cells, selegiline didn’t affect αS uptake, solubility and viability of recipient neurons compared to PBS.

Conclusion: These findings show that selegiline drives autophagy-based secretion of αS through affecting intracellular Ca2+ concentration and amphisome formation. Selegiline don’t affect exosomal and lysosomal αS secretions. Additionally, selegiline-induced αS secretion don’t facilitate cell-to-cell transmission of αS.

Table

References: 1. Nakamura Y, Arawaka S, Sato H, Sasaki A, Shigekiyo T, Takahata K, Tsunekawa H, Kato T. Monoamine oxidase-B inhibition facilitates α-synuclein secretion in vitro and delays its aggregation in rAAV-based rat models of Parkinson’s disease. Journal of Neuroscience. 2021;41:7479-91.

To cite this abstract in AMA style:

Y. Nakamura, S. Arawaka. Selegiline drives autophagic secretion of α-synuclein [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/selegiline-drives-autophagic-secretion-of-%ce%b1-synuclein/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/selegiline-drives-autophagic-secretion-of-%ce%b1-synuclein/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley